Javid J. Moslehi, M.D.
Dr. Javid Moslehi is the Director of the Cardio-Oncology Program and an Assistant Professor of Medicine at Vanderbilt. Dr. Moslehi is also a physician-scientist whose laboratory is interested in elucidating the mechanisms of cardiovascular and cardiometabolic complications associated with targeted cancer therapies. In 2009, Dr. Moslehi founded the cardio-oncology program at Brigham and Women’s Hospital and Dana-Farber Cancer Institute at Harvard Medical School before being recruited to direct the cardio-oncology program at Vanderbilt in 2014. With the help of colleagues at Vanderbilt and collaborators nationally, Dr. Moslehi has established preventive and treatment strategies for attenuating cardiovascular disease in cancer patients and cancer survivors. For more information about the cardio-oncology program, please contact email@example.com.
David A. Slosky, M.D.
Professor of Medicine
Dr. Slosky is an Assistant Professor of Medicine and a co-founder of the cardiovascular oncology program at Vanderbilt University Medical Center. He has a special interest in the care of patients with cancer and complications of cancer therapy, risk of heart disease, and pre-existing cardiovascular disease. He has an active clinical practice that bridges the two specialties and provides focused care for these patients during their therapy and into survivorship. He has developed a multi-disciplinary group of collaborators that bring expertise and precision care for cancer patients. An example of this effort involves clinical and basic research in the field of thrombosis (blood clots) in patients with cancer. This is a major problem for these individuals and this effort is a unique example of translational research from the bedside to the bench. Dr. Slosky is board certified in Internal Medicine, Cardiovascular Disease, and Interventional Cardiology.
Thomas Force, M.D.,
Dr. Force is a Professor of medicine and Director of Cardiovascular Research at Vanderbilt. Since 1986, he has focused his research on molecular mechanisms of injury to the heart, especially as a result of perturbations in protein kinase signaling. The emergence of novel tyrosine kinase inhibitors used in cancer therapy and their potential cardiac complications brought a translational aspect to his research program. Since 2005, he has tried to identify molecular mechanisms of toxicity. Dr. Force graduated from Harvard College and Harvard Medical School and is board certified in internal medicine and cardiology. Prior to moving to Vanderbilt, he was clinical director at the center for translational medicine and a professor of Medicine at Temple University School of Medicine. He is a former president of Heart Failure Society of America.